Rocket Pharmaceuticals, Inc. (RCKT) entered into a sales agreement with Cantor Fitzgerald & Co. for an at‑the‑market (ATM) offering of up to $100 million in new equity. The shares will be issued under an existing shelf registration statement on Form S‑3, with a prospectus supplement filed on March 10, 2026. Cantor Fitzgerald will receive a commission of up to 3.0 % of gross proceeds, and the company has terminated its prior ATM agreement with Cowen and Company, LLC.
The ATM offering comes as Rocket’s financial position reflects a net loss of $42.5 million for Q4 2025, an improvement from $60.3 million in Q4 2024, and a full‑year 2025 loss of $223.1 million versus $258.7 million in 2024. As of December 31, 2025, the company held $188.9 million in cash, cash equivalents, and investments, which it projected would fund operations into the second quarter of 2027. The new capital raise is intended to provide flexible liquidity to support ongoing clinical programs and to extend the company’s runway as it continues to invest in its gene‑therapy pipeline.
Strategically, Rocket has refocused its pipeline on its AAV cardiovascular gene‑therapy platform, pausing investment in Fanconi Anemia (RP‑L102) and Pyruvate Kinase Deficiency (RP‑L301) programs. The company’s CEO, Gaurav Shah, has emphasized strengthening leadership in cardiovascular gene therapy and maintaining rigorous clinical execution. The ATM offering will help fund the prioritized cardiovascular programs, including Phase 2 work on RP‑A501 for Danon disease and the PDUFA‑date program KRESLADI™ for severe LAD‑I.
The agreement allows Rocket to sell shares at prevailing market prices, providing the company with a flexible source of capital that can be drawn down as needed. The up‑to‑$100 million ceiling gives management discretion to balance dilution against the need for additional cash to sustain clinical development and operational expenses. By extending its cash runway, Rocket can continue to advance its cardiovascular pipeline without the immediate pressure of raising additional debt or equity through a traditional offering.
Overall, the ATM offering represents a significant capital‑raising event that enhances Rocket’s liquidity position, supports its strategic shift toward cardiovascular gene therapy, and extends the company’s financial runway into 2027. The transaction underscores management’s commitment to maintaining a disciplined cost structure while pursuing high‑impact clinical programs.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.